Petros pharmaceuticals announces pricing of $9.6 million public offering of common stock and warrants

New york, ny / access newswire / february 18, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over-the-counter ("otc") drug development programs, today announces the pricing of a public offering of approximately 40,000,000 shares of the company's common stock ("common stock"), par value $0.0001 per share (or pre-funded warrants in lieu thereof), with each share of common stock (or pre-funded warrant) accompanied by (i) a series a warrant to purchase 0.25 share of common stock at an exercise price of $0.48 per 0.25 share ("series a warrant") and (ii) a series b warrant to purchase one (1) share of common stock at an exercise price of $0.48 per share ("series b warrant"). the combined public offering price of each share of common stock together with the accompanying series a warrant and series b warrant is $0.24, and the combined public offering price of each pre-funded warrant together with the accompanying series a warrant and series b warrant is $0.2399, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant.
PTPI Ratings Summary
PTPI Quant Ranking